Humacyte, Inc. (NASDAQ:HUMA) Receives $10.00 Consensus PT from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.00.

Several analysts have recently commented on HUMA shares. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a report on Friday, September 20th.

Humacyte Stock Performance

Shares of HUMA opened at $5.39 on Wednesday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. The firm’s fifty day simple moving average is $5.57 and its two-hundred day simple moving average is $6.10. Humacyte has a 12 month low of $2.02 and a 12 month high of $9.97. The stock has a market capitalization of $643.30 million, a P/E ratio of -4.28 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). As a group, analysts predict that Humacyte will post -1.09 EPS for the current year.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 157,704 shares of Humacyte stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $5.42, for a total transaction of $854,755.68. Following the completion of the transaction, the chief executive officer now owns 3,519,558 shares in the company, valued at approximately $19,076,004.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Laura E. Niklason sold 157,704 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the sale, the chief executive officer now directly owns 3,519,558 shares of the company’s stock, valued at $19,076,004.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock worth $6,869,996 in the last quarter. Insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors have recently made changes to their positions in the company. nVerses Capital LLC bought a new position in shares of Humacyte during the second quarter valued at about $28,000. Hartline Investment Corp purchased a new stake in Humacyte in the 1st quarter valued at about $70,000. Concurrent Investment Advisors LLC purchased a new stake in Humacyte in the 3rd quarter valued at about $75,000. Principal Financial Group Inc. bought a new position in shares of Humacyte during the 2nd quarter worth approximately $83,000. Finally, Profund Advisors LLC purchased a new position in shares of Humacyte in the 2nd quarter worth approximately $97,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.